On November 18, 2021 Scandion Oncology reported its third quarter report for 2021 (Press release, Scandion Oncology, NOV 18, 2021, View Source,c3455924 [SID1234595765]). The following is taken from the report.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bo Rode Hansen, President and CEO comments
"During the third quarter, Scandion Oncology has continued the transformation towards the Cancer Drug Resistance company according to the company’s strategy. We completed the first Capital Markets Day where we conveyed the strategy for the registrational path to market of our clinical programs."
Highlights during Q3 2021
On August 25, Scandion Oncology announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101. The granted patent covers combination therapy with Scandion Oncology’s first-in-class lead candidate SCO-101. The patent claims the use of SCO-101 in combination with different anti-cancer agents across many cancer indications.
On August 27, Scandion Oncology announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study.
On September 2, Scandion Oncology and Alligator Bioscience announced the conclusion of their collaboration with a very positive outcome.
On September 6, Scandion Oncology announced that the company has obtained approval from the Danish Medicines Agency and the Ethics Committee of the amendment of part 2 of the CORIST Phase II study. This means that the company can commence the inclusion of patients. To increase the recruitment rate, Scandion Oncology is expanding the number of sites in Denmark from 2 to 5 and plans to further add additional sites in the EU.
On September 7, Scandion Oncology announced that the company has strengthened its Clinical Advisory Board with three international highly experienced Key Opinion Leaders in oncology.
On September 8, Scandion Oncology announced it will provide novel information on its lead candidate drug SCO-101 and a focused clinical strategy with a clear path to registration at its Capital Markets Day. The company will also communicate about its pipeline, future business opportunities and give an update from part 1 of the CORIST Phase II study.
Highlights after the end of the period
November 8, Scandion Oncology announced that the timeline for read-out of the dose-finding clinical Phase Ib study PANTAX will be extended, and read-out is now expected in Q2-Q3 2022.
The third quarter report 2021 is available on the Company’s website: www.scandiononcology.com.
Audiocast today, November 18 at 10:00 am CET
Today at 10:00 Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on November 18, 2021, at 8:30 CET